Yi Cao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yi Cao has a total of 130 co-authors. Here are the top co-authors by number of shared publications:
Zheng Lin
Graduate School, Tianjin University of Traditional Chinese Medicine
9 shared publications- Ping Lin
Geriatric department, Hangzhou Third People’s Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, China
6 shared publications Hong-Fei Wang
The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine)
4 shared publications- Maocan Tao
The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine)
4 shared publications - Qiujun Zhou
The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China
4 shared publications - Qiushuang Li
Center of Clinical Evaluation and Analysis, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine)
4 shared publications
Latest Publications
- Open Access
- 29 October 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1975921
Neurodevelopmental disorders in pediatric patients with atopic dermatitis: a systematic review and meta-analysis
Background: Neurodevelopmental disorders (NDs) are increasingly recognized among children with atopic dermatitis (AD). This systematic review and meta-analysis aimed to summarize the prevalence of NDs in pediatric patients with AD and quantify the associations between AD and specific neurodevelopmental outcomes. Methods: We searched Embase, PubMed, Cochrane Library, Web of Science, and PsycINFO from their inception to 1 December 2025. Observational studies reporting adjusted estimates and/or prevalence for NDs in pediatric patients with AD were included. Exploratory subgroup analyses were undertaken to ascertain sources of heterogeneity. Funnel plots and Egger's test were used to assess publication bias. Results: From 2,514 initial records, 39 studies reporting ND outcomes in pediatric patients with AD were included. The pooled prevalence rates for NDs were as follows: attention-deficit/hyperactivity disorder (ADHD, 6.01%), autism spectrum disorder (ASD, 0.81%), learning disability (LD, 11.34%), conduct disorder (CD, 2.76%), and peer problems (5.98%). AD was associated with higher odds of ADHD (OR = 1.34, 95% CI, 1.21–1.50), ASD (OR = 2.11, 95% CI, 1.07–4.16), LD (OR = 1.71, 95% CI, 1.41–2.06), intellectual disability (OR = 1.39, 95% CI, 1.33–1.45), and CD (OR = 1.35, 95% CI, 1.16–1.58), but not peer problems (OR = 1.10, 95% CI, 0.96–1.26). HR-based estimates for ADHD (HR = 1.54, 95% CI, 0.97–2.44) and ASD (HR = 2.09, 95% CI, 0.54–8.19) were directionally similar but less precise. Substantial heterogeneity was present across several analyses. Conclusion: Pediatric AD was associated with higher odds of several neurodevelopmental outcomes compared with children without AD. However, substantial heterogeneity, potential detection bias, and the observational nature of the available evidence limit causal interpretation. Further well-designed longitudinal studies using standardized exposure and outcome definitions, adequate control of confounding, and clearer temporal characterization are needed to clarify the consistency and directionality of these associations. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024545405 , PROSPERO CRD42024545405.
- 29 October 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1975921
Open AccessNeurodevelopmental disorders in pediatric patients with atopic dermatitis: a systematic review and meta-analysis
Background: Neurodevelopmental disorders (NDs) are increasingly recognized among children with atopic dermatitis (AD). This systematic review and meta-analysis aimed to summarize the prevalence of NDs in pediatric patients with AD and quantify the associations between AD and specific neurodevelopmental outcomes. Methods: We searched Embase, PubMed, Cochrane Library, Web of Science, and PsycINFO from their inception to 1 December 2025. Observational studies reporting adjusted estimates and/or prevalence for NDs in pediatric patients with AD were included. Exploratory subgroup analyses were undertaken to ascertain sources of heterogeneity. Funnel plots and Egger's test were used to assess publication bias. Results: From 2,514 initial records, 39 studies reporting ND outcomes in pediatric patients with AD were included. The pooled prevalence rates for NDs were as follows: attention-deficit/hyperactivity disorder (ADHD, 6.01%), autism spectrum disorder (ASD, 0.81%), learning disability (LD, 11.34%), conduct disorder (CD, 2.76%), and peer problems (5.98%). AD was associated with higher odds of ADHD (OR = 1.34, 95% CI, 1.21–1.50), ASD (OR = 2.11, 95% CI, 1.07–4.16), LD (OR = 1.71, 95% CI, 1.41–2.06), intellectual disability (OR = 1.39, 95% CI, 1.33–1.45), and CD (OR = 1.35, 95% CI, 1.16–1.58), but not peer problems (OR = 1.10, 95% CI, 0.96–1.26). HR-based estimates for ADHD (HR = 1.54, 95% CI, 0.97–2.44) and ASD (HR = 2.09, 95% CI, 0.54–8.19) were directionally similar but less precise. Substantial heterogeneity was present across several analyses. Conclusion: Pediatric AD was associated with higher odds of several neurodevelopmental outcomes compared with children without AD. However, substantial heterogeneity, potential detection bias, and the observational nature of the available evidence limit causal interpretation. Further well-designed longitudinal studies using standardized exposure and outcome definitions, adequate control of confounding, and clearer temporal characterization are needed to clarify the consistency and directionality of these associations. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024545405 , PROSPERO CRD42024545405.
- Open Access
- 11 August 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1) , 24897
Construction and validation of a prediction system for postherpetic neuralgia: based on meta-analysis
Postherpetic neuralgia (PHN) is a chronic and intractable pain disorder. Existing PHN prediction systems have limited clinical applicability. A systematic search of the literature was conducted in PubMed, Web of Science, Embase and the Cochrane Library between 1950 and 2025, finally 44 studies were included (PROSPERO: CRD420251011300). Training (n = 417) and validation (n = 228) datasets were obtained from First Affiliated Hospital of Zhejiang Chinese Medical University and Third People’s Hospital of Hangzhou. Based on the effect sizes from the meta-analysis, a linear regression model was fitted using the training set to develop the PHN Prediction Scoring Scale (PPSS), which was subsequently validated in the independent validation set. Seven key risk factors identified from the meta-analysis were selected for scoring,, including age (odds ratio(OR) (95% confidence interval): 1.66 (1.47, 1.88)), acute pain (OR: 2.61 (2.24, 3.05)), prodromal pain (OR: 1.79 (1.38, 2.31)), severe rash (OR: 2.64 (1.95, 3.56)), rash on the head(OR: 1.96 (1.8, 2.13)), diabetes (OR: 1.34 (1.24, 1.44)), immunosuppression (OR: 2.23 (1.95, 2.56)). Based on the above factors and weights, the PPSS were constructed. The results showed that on the validation set the area under curve of PPSS was 0.759 (0.693–0.824), accuracy was 0.684 (0.624–0.745), precision was 0.515 (0.417–0.612), recall was 0.693 (0.589–0.798), specificity was 0.680 (0.606–0.754). These findings suggest that the PPSS holds promise for generalization and application in clinical practice.
- 11 August 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1) , 24897
Open AccessConstruction and validation of a prediction system for postherpetic neuralgia: based on meta-analysis
Postherpetic neuralgia (PHN) is a chronic and intractable pain disorder. Existing PHN prediction systems have limited clinical applicability. A systematic search of the literature was conducted in PubMed, Web of Science, Embase and the Cochrane Library between 1950 and 2025, finally 44 studies were included (PROSPERO: CRD420251011300). Training (n = 417) and validation (n = 228) datasets were obtained from First Affiliated Hospital of Zhejiang Chinese Medical University and Third People’s Hospital of Hangzhou. Based on the effect sizes from the meta-analysis, a linear regression model was fitted using the training set to develop the PHN Prediction Scoring Scale (PPSS), which was subsequently validated in the independent validation set. Seven key risk factors identified from the meta-analysis were selected for scoring,, including age (odds ratio(OR) (95% confidence interval): 1.66 (1.47, 1.88)), acute pain (OR: 2.61 (2.24, 3.05)), prodromal pain (OR: 1.79 (1.38, 2.31)), severe rash (OR: 2.64 (1.95, 3.56)), rash on the head(OR: 1.96 (1.8, 2.13)), diabetes (OR: 1.34 (1.24, 1.44)), immunosuppression (OR: 2.23 (1.95, 2.56)). Based on the above factors and weights, the PPSS were constructed. The results showed that on the validation set the area under curve of PPSS was 0.759 (0.693–0.824), accuracy was 0.684 (0.624–0.745), precision was 0.515 (0.417–0.612), recall was 0.693 (0.589–0.798), specificity was 0.680 (0.606–0.754). These findings suggest that the PPSS holds promise for generalization and application in clinical practice.
- Open Access
- 2 March 2026
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 16, 1704547
Diet-induced dampness-heat psoriasis is characterized by reduced Lactobacillus and accumulation of deoxycholic acid
Background: Psoriasis is a common immune-mediated skin disease influenced by environmental and dietary factors. In traditional Chinese medicine (TCM), endogenous dampness-heat syndrome, often induced by diets rich in stimulating foods, is considered a trigger that aggravates psoriasis. However, the underlying mechanisms remain unclear. This study investigated the gut microbiota and metabolic alterations associated with endogenous dampness-heat syndrome in psoriasis. Materials and methods: BALB/c mice were fed a stimulating food diet to establish a model of endogenous dampness-heat syndrome, followed by the induction of psoriasis-like dermatitis by applying imiquimod. Mice on a standard diet served as disease controls and healthy controls. Characteristics of the gut microbiota were analyzed by 16S rDNA sequencing. UPLC–MS/MS was used to detect metabolic changes in the feces and serum of mice and to quantify multiple bile acids. Lipid accumulation and bile acid content in the liver were evaluated by Oil Red O staining and total bile acid assays. Results: Endogenous dampness-heat modeling aggravated psoriasis-like symptoms in mice. This was accompanied by marked dysbiosis of the gut microbiota, characterized by reduced abundance of Lactobacillus and Bacteroides . Serum and fecal metabolomics revealed prominent alterations in bile acid metabolism, closely associated with the reduction in Lactobacillus . Targeted quantification confirmed elevated deoxycholic acid in serum, together with increased total bile acids and lipid deposition in the liver. The expression of FXR in bile acid pathway in the liver was decreased, while the expression of CYP7A1 was increased. Conclusion: The exacerbation of skin lesions and hepatic lipid deposition in endogenous dampness-heat pattern psoriasis may be associated with bile acid imbalance and reduced Lactobacillus levels.
- 2 March 2026
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 16, 1704547
Open AccessDiet-induced dampness-heat psoriasis is characterized by reduced Lactobacillus and accumulation of deoxycholic acid
Background: Psoriasis is a common immune-mediated skin disease influenced by environmental and dietary factors. In traditional Chinese medicine (TCM), endogenous dampness-heat syndrome, often induced by diets rich in stimulating foods, is considered a trigger that aggravates psoriasis. However, the underlying mechanisms remain unclear. This study investigated the gut microbiota and metabolic alterations associated with endogenous dampness-heat syndrome in psoriasis. Materials and methods: BALB/c mice were fed a stimulating food diet to establish a model of endogenous dampness-heat syndrome, followed by the induction of psoriasis-like dermatitis by applying imiquimod. Mice on a standard diet served as disease controls and healthy controls. Characteristics of the gut microbiota were analyzed by 16S rDNA sequencing. UPLC–MS/MS was used to detect metabolic changes in the feces and serum of mice and to quantify multiple bile acids. Lipid accumulation and bile acid content in the liver were evaluated by Oil Red O staining and total bile acid assays. Results: Endogenous dampness-heat modeling aggravated psoriasis-like symptoms in mice. This was accompanied by marked dysbiosis of the gut microbiota, characterized by reduced abundance of Lactobacillus and Bacteroides . Serum and fecal metabolomics revealed prominent alterations in bile acid metabolism, closely associated with the reduction in Lactobacillus . Targeted quantification confirmed elevated deoxycholic acid in serum, together with increased total bile acids and lipid deposition in the liver. The expression of FXR in bile acid pathway in the liver was decreased, while the expression of CYP7A1 was increased. Conclusion: The exacerbation of skin lesions and hepatic lipid deposition in endogenous dampness-heat pattern psoriasis may be associated with bile acid imbalance and reduced Lactobacillus levels.
- 16 February 2026
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 95 (1) , e57-e58
Response to Bingyang Xu et al’s “Optimized combination: Isotretinoin in conjunction with oral tranexamic acid for the treatment of moderate to severe acne vulgaris—A randomized, double-blind, placebo-controlled trial”
- 16 February 2026
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 95 (1) , e57-e58
Response to Bingyang Xu et al’s “Optimized combination: Isotretinoin in conjunction with oral tranexamic acid for the treatment of moderate to severe acne vulgaris—A randomized, double-blind, placebo-controlled trial”
- Open Access
- 20 January 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Sesamin alleviates androgenetic alopecia by targeting the AR MAPK Wnt axis
Androgenetic alopecia (AGA) represents the most common form of hair loss, yet it lacks truly effective therapeutic options. Sesamum has been used for treating hair loss by ancient Chinese doctors. Nevertheless, the mechanism of sesamum is unclear. Sesamin is a key ingredient in sesamum, which shows multiple biological activities. We proposed that sesamin might improve influence molecular processes relevant to AGA by regulating the growth cycling of skin cells, and elucidated our proposal with in vitro researches. Network pharmacology was employed to predict sesamin–AGA targets and pathways. High-confidence targets were mapped into a protein–protein interaction network and functionally annotated by GO and KEGG enrichment. Molecular docking quantified binding affinities between sesamin and key proteins. Cytotoxicity was assessed by MTT in HaCaT keratinocytes. The regulatory capacity of sesamin was validated in DHT-stimulated HaCaT cells by Western blotting for AR, p38 MAPK, apoptosis (BAX/BCL2) and WNT10B signaling. Fifteen overlapping targets were identified, with AR, EGFR, ESR1 and CASP3 forming the core network. Enrichment analyses highlighted steroid hormone response, cell proliferation and MAPK/Wnt cascades. Docking showed high-affinity binding of sesamin to AR (− 9.1 kcal·mol⁻¹). Cell assays revealed that 10–80 µM sesamin reversed DHT-induced p38 phosphorylation, normalized AR expression, down-regulated pro-apoptotic BAX, restored anti-apoptotic BCL2, and elevated WNT10B. Our findings provided mechanistic evidences that sesamin modulates the AR-MAPK-Wnt signaling axis in DHT-challenged HaCaT cells, suggesting its potential multi-target activity against molecular events implicated in androgenetic alopecia.
- 20 January 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessSesamin alleviates androgenetic alopecia by targeting the AR MAPK Wnt axis
Androgenetic alopecia (AGA) represents the most common form of hair loss, yet it lacks truly effective therapeutic options. Sesamum has been used for treating hair loss by ancient Chinese doctors. Nevertheless, the mechanism of sesamum is unclear. Sesamin is a key ingredient in sesamum, which shows multiple biological activities. We proposed that sesamin might improve influence molecular processes relevant to AGA by regulating the growth cycling of skin cells, and elucidated our proposal with in vitro researches. Network pharmacology was employed to predict sesamin–AGA targets and pathways. High-confidence targets were mapped into a protein–protein interaction network and functionally annotated by GO and KEGG enrichment. Molecular docking quantified binding affinities between sesamin and key proteins. Cytotoxicity was assessed by MTT in HaCaT keratinocytes. The regulatory capacity of sesamin was validated in DHT-stimulated HaCaT cells by Western blotting for AR, p38 MAPK, apoptosis (BAX/BCL2) and WNT10B signaling. Fifteen overlapping targets were identified, with AR, EGFR, ESR1 and CASP3 forming the core network. Enrichment analyses highlighted steroid hormone response, cell proliferation and MAPK/Wnt cascades. Docking showed high-affinity binding of sesamin to AR (− 9.1 kcal·mol⁻¹). Cell assays revealed that 10–80 µM sesamin reversed DHT-induced p38 phosphorylation, normalized AR expression, down-regulated pro-apoptotic BAX, restored anti-apoptotic BCL2, and elevated WNT10B. Our findings provided mechanistic evidences that sesamin modulates the AR-MAPK-Wnt signaling axis in DHT-challenged HaCaT cells, suggesting its potential multi-target activity against molecular events implicated in androgenetic alopecia.
- Open Access
- 20 December 2025
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 17 (1)
Efficacy and safety of stem cell therapy in patients with chronic lower extremity ulcers: an umbrella review of systematic reviews and meta-analyses
Chronic lower extremity ulcers (CLEUs) remain a major clinical challenge due to their prolonged healing process and risk of amputation. Stem cell therapy (
- 20 December 2025
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 17 (1)
Open AccessEfficacy and safety of stem cell therapy in patients with chronic lower extremity ulcers: an umbrella review of systematic reviews and meta-analyses
Chronic lower extremity ulcers (CLEUs) remain a major clinical challenge due to their prolonged healing process and risk of amputation. Stem cell therapy (
- 22 November 2025
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 357, 120943
Jieduquyuziyin prescription regulates the differentiation of Tfh cells in systemic lupus erythematosus through lysophosphatidyl ethanolamine metabolism
- 22 November 2025
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 357, 120943
Jieduquyuziyin prescription regulates the differentiation of Tfh cells in systemic lupus erythematosus through lysophosphatidyl ethanolamine metabolism
- Open Access
- 14 November 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (46) , e45425
Apalutamide-induced life-threatening dermatologic toxicity: Clinical histopathological correlations and salvage therapies in four cases: Case report series
Rationale: Apalutamide is a novel next-generation oral antiandrogen receptor targeting agent for castration-resistant prostate cancer. However, it is associated with skin adverse events (AEs), which have been reported in clinical trials but are not fully understood due to limited clinical data. This case report explored the clinical presentation and management of apalutamide-associated skin events through 4 representative cases. Patient concerns: Four male patients with prostate cancer developed various skin rashes after taking apalutamide. The rashes were characterized by different manifestations, including erythema, itching, flaking, swelling, and even mucosal erosion, which significantly affected the patients’ quality of life and required prompt intervention. Diagnoses: Based on the clinical presentation and histopathological examination of the skin, the diagnoses included eczema and severe drug rashes such as toxic epidermal necrolysis and Stevens–Johnson syndrome. The incubation periods of the rashes ranged from 1 week to 2 months, and some patients also exhibited other symptoms like elevated white blood cell count, eosinophilia, increased C-reactive protein and lactate dehydrogenase levels, lymph node enlargement, fever, liver damage, and nail dystrophy. Interventions: All patients discontinued the use of apalutamide. They were treated with oral antihistamines and topical glucocorticoid ointment. Three cases received systemic glucocorticoid therapy, and 1 case was administered Duplizumab. The treatment strategies were adjusted according to the severity and progression of the rashes. Outcomes: The rashes gradually improved after the discontinuation of apalutamide and the initiation of appropriate treatment. In one case, the rash reappeared after the patient self-administered apalutamide again, but it subsided on its own after discontinuation of the drug. The symptoms of the other patients were well controlled, and no significant complications were observed during the follow-up period. Lessons: This case report highlights the importance of recognizing and managing apalutamide-associated skin AEs. The development of these AEs appears to be dose-dependent, and early discontinuation or dose reduction of the drug is crucial for controlling the symptoms. A multidisciplinary approach involving oncologists and dermatologists is recommended to optimize the treatment strategy and maintain the patients’ quality of life.
- 14 November 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (46) , e45425
Open AccessApalutamide-induced life-threatening dermatologic toxicity: Clinical histopathological correlations and salvage therapies in four cases: Case report series
Rationale: Apalutamide is a novel next-generation oral antiandrogen receptor targeting agent for castration-resistant prostate cancer. However, it is associated with skin adverse events (AEs), which have been reported in clinical trials but are not fully understood due to limited clinical data. This case report explored the clinical presentation and management of apalutamide-associated skin events through 4 representative cases. Patient concerns: Four male patients with prostate cancer developed various skin rashes after taking apalutamide. The rashes were characterized by different manifestations, including erythema, itching, flaking, swelling, and even mucosal erosion, which significantly affected the patients’ quality of life and required prompt intervention. Diagnoses: Based on the clinical presentation and histopathological examination of the skin, the diagnoses included eczema and severe drug rashes such as toxic epidermal necrolysis and Stevens–Johnson syndrome. The incubation periods of the rashes ranged from 1 week to 2 months, and some patients also exhibited other symptoms like elevated white blood cell count, eosinophilia, increased C-reactive protein and lactate dehydrogenase levels, lymph node enlargement, fever, liver damage, and nail dystrophy. Interventions: All patients discontinued the use of apalutamide. They were treated with oral antihistamines and topical glucocorticoid ointment. Three cases received systemic glucocorticoid therapy, and 1 case was administered Duplizumab. The treatment strategies were adjusted according to the severity and progression of the rashes. Outcomes: The rashes gradually improved after the discontinuation of apalutamide and the initiation of appropriate treatment. In one case, the rash reappeared after the patient self-administered apalutamide again, but it subsided on its own after discontinuation of the drug. The symptoms of the other patients were well controlled, and no significant complications were observed during the follow-up period. Lessons: This case report highlights the importance of recognizing and managing apalutamide-associated skin AEs. The development of these AEs appears to be dose-dependent, and early discontinuation or dose reduction of the drug is crucial for controlling the symptoms. A multidisciplinary approach involving oncologists and dermatologists is recommended to optimize the treatment strategy and maintain the patients’ quality of life.
- Open Access
- 15 September 2025
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 16, 1632682
Evaluating the efficacy of machine learning in predicting postherpetic neuralgia: a systematic review and meta-analysis
Introduction: The prediction of postherpetic neuralgia (PHN) is of great clinical significance. PHN prediction based on machine learning have received extensive attention in recent years. This study aims to conduct a comprehensive evaluation of machine learning in PHN prediction and provide guidance for the future models.Method: The system retrieved the relevant literatures published in the PubMed, Web of Science, Embase and Cochrane Library databases from the establishment of the database to May 2025. Literature screening and data extraction were conducted in accordance with the PRISMA guidelines. According to the heterogeneity, the fixed-effect or the random-effect model was selected for data synthesis. The potential sources of heterogeneity were further explored through subgroup analysis, sensitivity tests and meta-regression. Funnel plots and Deeks’ tests were used to evaluate the possible publication biases.Result: The main meta-analysis included 41 models from 14 studies. The results showed that machine learning demonstrated excellent performance in predicting PHN (sensitivity: 0.81, 95% confidence interval (CI): 0.74–0.86; specificity: 0.84, 95% CI: 0.79–0.88; area under the curve: 0.90, 95% CI: 0.87–0.92). Meta-regression analysis indicates that the source of the data set, model selection, and the choice of predictors are the main reasons leading to heterogeneity. Subgroup analysis showed that the training set model outperformed the validation set model. Logistic regression and other machine learning had varying strengths and weaknesses. Serum data or omics analysis did not significantly enhance model performance.Conclusion: Machine learning represents a promising approach for the prediction of PHN. However, most of the existing models face issues like lack of external validation, overfitting, and insufficient reporting standardization. This has raised doubts about whether the current PHN prediction models can still maintain a high prediction accuracy when extended to external data. To improve future models, we recommend conducting strict external validation, clearly reporting cutoff values (balanced, positive, and negative), and adhering to international predictive model reporting standards. When applicable, ensemble learning and pain trajectory analyses should also be considered.Systematic review registration: This study was registered in the Prospective Register of Systematic Reviews (PROSPERO; CRD420251054364).
- 15 September 2025
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 16, 1632682
Open AccessEvaluating the efficacy of machine learning in predicting postherpetic neuralgia: a systematic review and meta-analysis
Introduction: The prediction of postherpetic neuralgia (PHN) is of great clinical significance. PHN prediction based on machine learning have received extensive attention in recent years. This study aims to conduct a comprehensive evaluation of machine learning in PHN prediction and provide guidance for the future models.Method: The system retrieved the relevant literatures published in the PubMed, Web of Science, Embase and Cochrane Library databases from the establishment of the database to May 2025. Literature screening and data extraction were conducted in accordance with the PRISMA guidelines. According to the heterogeneity, the fixed-effect or the random-effect model was selected for data synthesis. The potential sources of heterogeneity were further explored through subgroup analysis, sensitivity tests and meta-regression. Funnel plots and Deeks’ tests were used to evaluate the possible publication biases.Result: The main meta-analysis included 41 models from 14 studies. The results showed that machine learning demonstrated excellent performance in predicting PHN (sensitivity: 0.81, 95% confidence interval (CI): 0.74–0.86; specificity: 0.84, 95% CI: 0.79–0.88; area under the curve: 0.90, 95% CI: 0.87–0.92). Meta-regression analysis indicates that the source of the data set, model selection, and the choice of predictors are the main reasons leading to heterogeneity. Subgroup analysis showed that the training set model outperformed the validation set model. Logistic regression and other machine learning had varying strengths and weaknesses. Serum data or omics analysis did not significantly enhance model performance.Conclusion: Machine learning represents a promising approach for the prediction of PHN. However, most of the existing models face issues like lack of external validation, overfitting, and insufficient reporting standardization. This has raised doubts about whether the current PHN prediction models can still maintain a high prediction accuracy when extended to external data. To improve future models, we recommend conducting strict external validation, clearly reporting cutoff values (balanced, positive, and negative), and adhering to international predictive model reporting standards. When applicable, ensemble learning and pain trajectory analyses should also be considered.Systematic review registration: This study was registered in the Prospective Register of Systematic Reviews (PROSPERO; CRD420251054364).
- Open Access
- 1 August 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1544218
Prevalence, incidence, and risk factors for herpes zoster in systemic lupus erythematosus: a systematic review and meta-analysis
Background: Patients with systemic lupus erythematosus (SLE) are particularly vulnerable to infections, with herpes zoster (HZ) being the most common opportunistic infection. This meta-analysis aimed to systematically review the available literature on the prevalence, incidence, and risk factors of HZ in SLE patients.Methods: A comprehensive search through Embase, PubMed, Web of Science, and Cochrane Library was conducted for studies published up to November 1, 2024. Both observational studies (including cohort, case-control, and cross-sectional) and randomized controlled trials (RCTs) were included, with study types selected according to the specific objectives. Funnel plots and Egger’s test were employed to assess publication bias. Hazard ratios (HRs) and odds ratios (ORs) were converted to relative risks (RRs), and pooled estimates were calculated using a fixed-effect or random-effects model.Results: A total of 51 studies with 246, 822 SLE patients were included in this meta-analysis. The pooled prevalence and incidence of SLE-HZ were 12.3% (95%CI 10.5-14.1) and 22.0 cases per 1000 person-years (95%CI 17.4-27.9). Glucocorticoids use (RRs=2.83, 95%CI 2.10-3.81), cyclophosphamide use (RRs=2.52, 95%CI 1.60-3.98), mycophenolate mofetil use (RRs=3.00, 95%CI 1.07-8.40), azathioprine use (RRs=1.40, 95%CI 1.18-1.67), anifrolumab use (RRs=2.59, 95%CI 1.52-4.41), having lymphopenia (RRs=2.31, 95%CI 1.54-3.46), and the presence of comorbid conditions such as renal involvement (RRs= 1.80, 95%CI 1.34-2.42) were identified to increase the risk of HZ in SLE patients.Conclusion: The existing evidence highlights the both high prevalence and incidence of HZ in SLE patients. By identifying risk factors associated with the development of HZ in SLE patients, optimization of management strategies and treatment choices can be achieved. Concurrently, physicians could be better equipped to choose patients who would most likely gain from the HZ vaccine.Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024331310, identifier CRD42024331310.
- 1 August 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1544218
Open AccessPrevalence, incidence, and risk factors for herpes zoster in systemic lupus erythematosus: a systematic review and meta-analysis
Background: Patients with systemic lupus erythematosus (SLE) are particularly vulnerable to infections, with herpes zoster (HZ) being the most common opportunistic infection. This meta-analysis aimed to systematically review the available literature on the prevalence, incidence, and risk factors of HZ in SLE patients.Methods: A comprehensive search through Embase, PubMed, Web of Science, and Cochrane Library was conducted for studies published up to November 1, 2024. Both observational studies (including cohort, case-control, and cross-sectional) and randomized controlled trials (RCTs) were included, with study types selected according to the specific objectives. Funnel plots and Egger’s test were employed to assess publication bias. Hazard ratios (HRs) and odds ratios (ORs) were converted to relative risks (RRs), and pooled estimates were calculated using a fixed-effect or random-effects model.Results: A total of 51 studies with 246, 822 SLE patients were included in this meta-analysis. The pooled prevalence and incidence of SLE-HZ were 12.3% (95%CI 10.5-14.1) and 22.0 cases per 1000 person-years (95%CI 17.4-27.9). Glucocorticoids use (RRs=2.83, 95%CI 2.10-3.81), cyclophosphamide use (RRs=2.52, 95%CI 1.60-3.98), mycophenolate mofetil use (RRs=3.00, 95%CI 1.07-8.40), azathioprine use (RRs=1.40, 95%CI 1.18-1.67), anifrolumab use (RRs=2.59, 95%CI 1.52-4.41), having lymphopenia (RRs=2.31, 95%CI 1.54-3.46), and the presence of comorbid conditions such as renal involvement (RRs= 1.80, 95%CI 1.34-2.42) were identified to increase the risk of HZ in SLE patients.Conclusion: The existing evidence highlights the both high prevalence and incidence of HZ in SLE patients. By identifying risk factors associated with the development of HZ in SLE patients, optimization of management strategies and treatment choices can be achieved. Concurrently, physicians could be better equipped to choose patients who would most likely gain from the HZ vaccine.Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024331310, identifier CRD42024331310.